Full Text
CC4 Cost-Benefit Analysis of Recombinant Erythropoietin in Premature Neonates

Abstract

Authors

TL Wandstrat SR Maxwell

Back to Volume 1, Issue 1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×